Coronary Artery Disease. Atherosclerotic heart disease of native coronary artery
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Existence of at least one of the major cardiovascular risk factors Willingness to participate in the study No consumption of any anti-inflammatory or antioxidant supplement such as omega-3, vitamin E, vitamin C and Selenium in last month
Exclusion criteria
Exclusion criteria: Unwillingness to continue Any changes in disease treatment plan such as changes in medical treatment or surgery Existence of gastrointestinal complications such as diarrhea
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lipoprotein-associated phospholipase A2 (Lp-PLA2). Timepoint: Baseline and the end of the study. Method of measurement: ELISA. | — |
Secondary
| Measure | Time frame |
|---|---|
| Plasma Lipoproteins. Timepoint: Baseline and the end of the study. Method of measurement: colorimetry.;Interleukin-6 (IL-6) & Monocyte Chemoattractant Protein-1 (MCP-1) in cultured whole blood. Timepoint: Baseline and the end of the study. Method of measurement: ELISA. | — |
Countries
Iran (Islamic Republic of)
Contacts
Shahid Beheshti University of Medical Sciences